I'm breaking down the ARR figures to identify the overstatement. The company claims $14.2M in ARR, but that's composed of $2.6M in one-time implementation fees, $1.1M in a signed-but-not-yet-live contract that's terminable, and $10.5M in actual recurring subscription revenue. That means the true recurring ARR is only $10.5M, representing a $3.7M overstatement or roughly 35% inflation of the actual recurring revenue.

This inflated ARR figure cascades into the valuation: at the stated $14.2M ARR with a $220M pre-money valuation, the multiple is 15.5x. But applying that same multiple to the true $10.5M recurring ARR yields only $163M pre-money—a $57M gap. I'm also factoring in the 9% subscription churn rate, which would reduce forward ARR to around $9.55M after four months, further compressing the valuation to roughly $148M.

The retention metrics are equally problematic. The company reported 138% net revenue retention, but the actual figure appears to be 111%—a 27 percentage point gap that fundamentally changes the growth profile and implied valuation. The exclusion of the two largest churned accounts from the retention calculation is a material misstatement about a historical fact. I'm now examining whether ARR and NRR qualify as present-fact statements or forward-looking projections under securities law, since that distinction affects what disclosure obligations and safe harbors apply.

The boilerplate forward-looking language doesn't address the specific risks here: the non-live contract, termination rights, inclusion of service fees, and the cohort exclusion methodology. Using a non-standard definition of "net revenue retention" without disclosure is misleading even if arithmetically defensible. The CFO's email about keeping the number true and adjusting after the round is direct evidence that management knew this was material to investors. The non-renewal notice received yesterday—9% of subscription revenue, roughly $945K—is a present historical fact and classic material non-public information that affects forward projections.

The retention narrative is central to the company's story, so losing the second-largest customer after already excluding two other major losses from the cohort compounds the materiality. The CFO's language shows actual knowledge and intent to defer correction until funding closes, establishing scienter; the CEO gains actual knowledge from this call going forward; and the board, if they approve signing without correction, faces their own scienter issues and potential breach of fiduciary duty. Industry practice around pipeline accounting doesn't legitimize an untrue statement.

For the anchor investor who already wired $8M under a signed agreement, the commitment is irrevocable, so Rule 10b-5(b) won't cut off reliance. The company should offer either full rescission with return of capital plus interest (strongest cure), or a repriced subscription agreement with additional shares reflecting the corrected valuation and documented informed consent. Doing nothing is not viable. Any rescission offer must be genuine, with complete corrected information, adequate time for the investor to consider, and no coercion or conditioning on other terms—and the company should recommend they get independent counsel.

The correction can't be a quiet fix; it needs written corrective disclosure. There's also the practical matter of the $8M return hitting the cap table and liquidity, so consider an escrow arrangement. If the anchor investor has a board seat or designee on the board, that person could become tainted by the knowledge of the misstatement.

If the anchor stays in at repriced terms, the amended subscription agreement combined with disclosure and a release of known claims substantially reduces exposure, though it doesn't eliminate it entirely—you can't waive prospective claims, but a negotiated settlement with full information is generally enforceable.

For the unsigned $32M commitment, the correction before irrevocable commitment cuts off reliance under Rule 10b-5(b), so the analysis shifts.

The restated disclosure needs to lay out the corrected ARR of $10.5M with a reconciliation showing services revenue at $2.6M and the non-live terminable portion at $1.1M with its 60-day termination right and go-live date, plus the ARR methodology, the prior 138% NRR figure and why it was wrong, and the non-renewal notice—either with customer identity or anonymized concentration data showing it's 9% of subscription revenue hitting in four months, which pro forma brings ARR down to around $9.55M. I also need to include the churn history covering the two large customer losses.

Beyond that, the disclosure should address the internal control failure and how it's being remedied, flag that the anchor investor is being offered rescission or repricing, and note the founder's secondary sale status. All financial statements and data room materials need correcting too, and the deck should be reissued as "Restated" with the old version formally withdrawn.

On the founder secondary piece, Rule 10b5 prevents selling while holding material nonpublic information to buyers who don't have it—so the non-renewal and restated metrics have to be disclosed first. The conditions are: full corrected disclosure to each purchaser, written acknowledgment they received it, pricing that reflects the corrected valuation at the repriced round price, and big-boy provisions to limit liability.

The real issue is the optics and litigation risk. Selling into a round while the company's metrics were overstated becomes Exhibit A in any lawsuit against her, and it looks like self-interested behavior that shows she knew about the problems. The board should seriously consider pulling or deferring the secondary entirely, and the founder needs independent counsel—especially if she's also on the board, which creates a conflict. The company can't consent away her personal duty here. My strong recommendation is to pull the secondary from this round, or at minimum defer it to after closing with proper disclosure and a structured process, because the reputational and legal exposure is just too high.

On the board side, they have a candor duty to shareholders when approving the financing and any charter amendments. Approving a financing they know rests on misleading materials is bad faith and a breach of loyalty, not just care, so it won't be protected by exculpation clauses. Fraud won't be covered by indemnification or D&O insurance, and the insurers may rescind coverage if they find out the board knew about the misstatement when renewing the policy—so we need to give them notice now. The CEO's proposal to "fix it for Series C" is conscious disregard, and any director who approves it should document their dissent. I'd recommend setting up an independent committee of disinterested directors with separate counsel, doing a forensic review of how the number was built, and making a personnel decision about the CFO at minimum.

We also need to preserve all documents—the CFO's email is in the diligence folder and cannot be deleted; spoliation would turn a fixable problem into obstruction. On repricing, we should present the corrected metrics as a reconciliation with a bridge table, disclose what we've done to fix it, and offer diligence access. The valuation will likely take a hit: at the same 15.5x multiple, the pre-money drops from $220M to around $163M on $10.5M revenue, and after accounting for the NRR decline to 111%, the multiple itself may compress due to lower growth quality, putting us realistically in the $130–165M range—a 25–40% haircut. Investors will also demand heavier terms like participating preferred, ratchets, and milestone tranches to protect themselves.

For the path forward, I'm weighing three options: delay to give us time to replace the non-renewal and clean up the metrics (though we need to check cash runway), reprice immediately to preserve honesty and the round, or restructure with milestone tranches and a valuation reset mechanism—or a smaller first close at a reduced pre-money with a price-based-on-milestones second tranche. The best approach is to correct the metrics now, offer investors a choice of terms, and reprice with a structured milestone tranche rather than delay; we should avoid any structure that obscures the actual price.

Now I'm mapping out the immediate 48-hour action plan: first, issue a litigation hold and stop all deck distribution immediately—instruct the deal team and bankers to cease sending it, suspend data room access to affected materials or add a corrective notice, and tell everyone to stop reaffirming the metrics verbally. I need to identify every recipient of the deck and document the distribution log, but leave the CFO email untouched. Engage independent counsel and notify the D&O carrier. Then over the next 6–18 hours, I'm having the CFO and controller rebuild the metrics under supervision—they'll produce a reconciliation, contract-level ARR schedule, cohort NRR recomputation, concentration table, and pro forma.

For hours 18–30, I'm drafting the corrective disclosure memo with restated metrics, a bridge showing the changes, methodology explanation, non-renewal analysis, and risk factors with specific cautionary language. I'll also draft a restated deck, an anchor letter with rescission versus amended terms options and a 10-business-day response window, a founder secondary decision memo, and board resolutions. By hours 30–42, we're at the board meeting on day 2 where they'll pass resolutions finding the prior materials materially misleading. notify the carrier; authorize repricing negotiation parameters. Over the next six days, I need to deliver the corrective disclosure to all investors simultaneously, schedule a call with them, and push the signing date out to day 20–25 to create a clean window for reliance. I'll also need to communicate with employees and shareholders as required for any consent solicitations. The $8M stays segregated and unspent during this period. On the ARR question, the $1.1M not-yet-live contract could potentially be included only if separately labeled as "contracted ARR" with termination rights disclosed, but the $2.6M in services fees is indefensible since services are non-recurring and can't be ARR.

The CFO's email is damaging—it shows conscious deviation from standard practice and an explicit intent to keep the inflated number until after the round closes, which points directly to scienter. The founder's $4M secondary sale adds motive and opportunity, especially if the founder and CEO are the same person. This also creates a fraud-on-the-seller exposure for the anchor and new investors, since they're relying on inflated metrics to price the deal, and the founder benefited personally from that misstatement.

Now I'm quantifying the materiality: the ARR overstatement is 35.2% of the true recurring base, with 26.1% of stated ARR being non-qualifying—either non-recurring services or a contract that's not live and terminable on 60 days' notice. The NRR impact is even starker: the stated 138% expansion premium versus the true 111% means the excess growth attributed to the existing customer base is 3.5 times smaller, which is the difference between a top-decile performer and a median company. At $220 per dollar of ARR, that's a massive valuation swing.

Looking at the multiples: the investor believes they're paying 15.5x on the stated $14.2M ARR, but they're actually paying 21x on the true $10.5M. Factoring in the 9% non-renewal rate drops the forward recurring base to $9.55M, pushing the actual multiple to 23x. So the represented figure overstates the durable revenue base by nearly 50% compared to what will actually recur. And the NRR will compress further next period as a result.

The exclusion of the two largest lost accounts isn't a definitional nuance—it's cherry-picking the denominator, which is a misstatement of historical fact.

On the "total mix" defense: even if a reconciliation existed somewhere in the data room, a buried document doesn't cure a headline misstatement in the deck. The diligence team only surfaced this discrepancy this week, so it wasn't part of what investors actually reviewed. And the $32M anchor already wired before anyone caught it.

I need to organize this into a structured memo with headers, keeping it dense but thorough—this is a complex multi-part analysis, so I'm aiming for around 1800–2500 words with efficient tables where needed.

For the $32M tranche on the unsigned term sheet: no irrevocable commitment yet means a corrected disclosure can still work, but I have to flag any side letters or exclusivity agreements that might have created binding obligations, and treat any investor who's already wired as anchor-like. The corrected disclosure needs to be delivered with enough lead time and affirmatively acknowledged in the subscription agreement—investor reps should state they received and reviewed the corrective memo, aren't relying on prior materials, and had a chance to ask questions. A "no reliance on prior deck" clause and integration clause help but won't shield against fraud; the real protection is the corrected disclosure itself.